Interpace Biosciences, Inc.
IDXGRESTATEMENT RISKFILING INTENSITYInterpace Biosciences, Inc. reads as Restatement Risk (composite 100/100); pressure / disclosure signals dominate the posture this cycle · primary market Life Sciences.
Lens
Disclosed M&A capital (2023–2025)
N/A
vs N/A in 2020–2022
Disclosed transactions
N/A
0/3 active fiscal years in window
Buyer archetype
Consistent Strategic Buyer
Meaningful spend appears across repeat years.
Composite score
100
Restatement Risk dominates · Filing Intensity
Behavioral posture, nine reads.
Each index scores the issuer 0–100 against an EDGAR-anchored definition. Scores ≥ threshold elevate the issuer into the index's constituent set; the dominant index drives the masthead label.
Active Acquirer
Companies actively deploying disclosed capital into M&A
- $376M disclosed buyer spend
Buyer Cadence
Buyer-side companies with recent filing activity
- Filed within 40d
- 332 8-Ks
Target Probability
Issuers showing target-side patterns from filings
- 24 activism filings
Spin/Carve
Issuers showing spin-off, carve-out, or sum-of-parts posture
- 24 activism filings
Pressure Watch
Issuers facing activism, governance, or control pressure
- 24 activism filings
- Latest activism 1.6y ago
Distress Watch
Issuers showing financial-distress filing patterns
- 10-Q 209d stale
- 24 activism filings
Restatement Risk
DominantIssuers with accounting-integrity flags from filings
- 3 non-reliance 8-Ks
- 3 auditor changes
- 5 NT late filings
- Latest event 1.3y ago
Capital Velocity
Issuers with the highest filing-activity intensity
- 332 8-Ks
- 5 form types
Quiet Power
Large issuers with low signal volume and clean disclosure cadence
- Enterprise value $7M
- 10-Q 209d ago
- 3 active signals
Capital cadence.
Ten-year disclosed M&A activity. Bars show spend ($MM); ticks show recorded transaction count. Disclosure tier annotated where v6 audited corpus carries an entry.
Disclosed spend $MM Disclosed transactions (right axis)Peak spend year: $21M · Peak count: 1
| FY | Disclosed buys | Disclosed spend | Avg ticket | Audited tier |
|---|---|---|---|---|
| 2025 | N/A | N/A | N/A | N/A |
| 2024 | N/A | N/A | N/A | N/A |
| 2023 | N/A | N/A | N/A | N/A |
| 2022 | N/A | N/A | N/A | N/A |
| 2021 | N/A | N/A | N/A | N/A |
| 2020 | N/A | $21M | N/A | N/A |
Strategy posture.
The buyer's playbook in terms of strategic archetype: what each disclosed move says about how they're deploying capital.
Archetype mix
- Bolt On20%
- Geographic Expansion20%
- Platform20%
- Horizontal Consolidation20%
- Tuck In20%
Strategy keywords
Terms recurring across recent 10-K acquisition disclosures.
- bolt_on
- geographic_expansion
- platform
- horizontal_consolidation
- tuck_in
- technology_acquisition
Filing language.
Direct excerpts from acquisition disclosures and strategy sections: the verbs the buyer chose, in the filings they signed.
“Cost-savings initiatives that will include reducing infrastructure costs, streamlining management, consolidating duplicative functions across both business units, and adapting to a remote work environment for non-laboratory personnel, which reduces the need for traditional office structures;”
“We realigned our reporting segments, and the operating segments and service offerings within our operating segments, due to the acquisition of RedPath and acquiring certain assets from Asuragen, to reflect our current and going forward business strategy.”
“Our strategy is to grow our business organically and by selectively partnering—which could potentially include licensing, acquisitions or mergers, to generate positive returns for our shareholders.”
“Consolidating facilities and related costs including leveraging and updating our Laboratory Information Systems (LIM’s) to provide timely and accurate lab information results;”
“Our current reporting segment structure is reflective of the way our management views the business, makes operating decisions and assesses performance.”
Market context.
Where this issuer sits inside its SE-Cluster rollup wedge, with disclosed-spend rank plus trading comparables against the public peer set.
Primary market
Life Sciences
- Market spend (2023–2025)
- $68.3B
- Market spend (2020–2022)
- $107.5B
- Recent vs prior
- −36%
- Issuer rank in market
- N/A
- Share of market capital
- 0.0%
Valuation positioning
IDXG trades at a -14.5-turn discount to the Life Sciences peer median of 16.1×.
- EV / Revenue
- 0.2×
- Net debt / EBITDA
- 0.4×
- Peer median EV / EBITDA
- 16.1×
Trading comparables
FMP market data · 2026-05-10
| Company | EV / EBITDA | EV / Rev | Net debt / EBITDA | Revenue | M&A 2023–2025 |
|---|---|---|---|---|---|
| 19.1× | 4.7× | -0.0× | $45.2B | $10.8B | |
| 18.8× | 4.3× | -0.3× | $20.6B | $8B | |
| 13.3× | 3.5× | -0.1× | $35.5B | $2.2B | |
| 13.1× | 1.9× | -0.2× | $14.1B | $2.1B | |
Interpace Biosciences, Inc.IDXG | 1.5× | 0.2× | 0.4× | $39M | N/A |
Trading multiples from FMP market data; disclosed M&A spend from the SE-Cluster EDGAR 10-K corpus. Peer set = top disclosed buyers in Life Sciences. Bars scaled to the highest EV/EBITDA in the set.
Buyer landscape.
Public buyers whose stated archetypes, target categories, and recent cadence align with this issuer as a plausible acquisition target. Scores cross EDGAR signal and disclosure overlap.
Likely buyers
No public buyers surface as a strong target-side fit on current signal.
Likely sellers / divestiture partners
No reciprocal divestiture / strategic-alternatives matches identified.
Filing activity & signal stream.
Filing cadence and event-driven signals visible on EDGAR. The signal stream below is curated from restatement / spin-carve / activism categories, providing context for any near-term call.
Filing cadence
- 10-K (annual)442026-04-30
- 10-Q (quarterly)922025-11-12
- 8-K (event)3322026-04-01
- Proxy / DEF 14A452024-09-20
- Activism (13D / DFAN / PREC)242024-10-16
Signals on file
- critical
Non-reliance disclosure
2025-03-063 Item 4.02 filings on file; financial-statement non-reliance.
- elevated
Auditor change
2022-04-143 Item 4.01 filings on file; certifying accountant change.
- watch
Late-filing notice
2021-04-015 NT 10-K/10-Q filings on file.
- elevated
Activism on file
2024-10-1624 activist filings on file (13D, DFAN14A, PREC14A series).
- info
Signal
Serial acquisition history
- info
Signal
10-K strategy themes
- info
Signal
Restatement risk
Audited corpus.
No audited record on file for this CIK in the current v6 corpus.
This issuer has not been extracted into the v6 audited acquirer corpus yet. The brief above pulls from ranking-level aggregates and issuer-index signal only.